Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
15.52 USD | -2.42% | -4.87% | 0.00% |
Apr. 15 | Leerink Partners Starts LENZ Therapeutics With Outperform Rating, $32 Price Target | MT |
Apr. 15 | William Blair Starts LENZ Therapeutics With Outperform Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
0.00% | 406M | |
+4.03% | 111B | |
+11.49% | 105B | |
-12.66% | 22.34B | |
-3.70% | 21.93B | |
-6.03% | 18.59B | |
-35.21% | 18.12B | |
-10.63% | 16.96B | |
+2.85% | 13.7B | |
+36.79% | 12.45B |
- Stock Market
- Equities
- LENZ Stock
- News LENZ Therapeutics, Inc.
- William Blair Starts LENZ Therapeutics With Outperform Rating